Charlotte, USA-based Chelsea Therapeutics says it has signed a letter of intent to acquire intellectual property rights relating to the synthetic amino acid L-Threo DOPS (L-DOPS or Droxidopa), which is owned by fellow US firm Synergia Pharma. Currently, the product is approved in Japan for the treatment of neurogenic orthostatic hypotension.
Chelsea added that it intends to seek Orphan Drug designation for Droxidopa from the Food and Drug Administration and European health agencies, for the treatment of NOH, on completion of the purchase.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze